223 related articles for article (PubMed ID: 28423588)
1. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Yang X; Tang C; Luo H; Wang H; Zhou X
Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
[TBL] [Abstract][Full Text] [Related]
2. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
3. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
Tang C; Luo H; Luo D; Yang H; Zhou X
Oncol Rep; 2018 Feb; 39(2):611-618. PubMed ID: 29207183
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
[TBL] [Abstract][Full Text] [Related]
6. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
7. [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
Qi Z; Wang Y; Zhou X
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1290-3. PubMed ID: 22985566
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
10. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
11. CA916798 regulates multidrug resistance of lung cancer cells.
Wang HJ; Yang HP; Zhou XD; Dai XT; Chen YF; Xiong W
Asian Pac J Cancer Prev; 2011; 12(12):3403-8. PubMed ID: 22471488
[TBL] [Abstract][Full Text] [Related]
12. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
[TBL] [Abstract][Full Text] [Related]
13. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
14. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
15. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
16. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY
Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer].
Zhan X; Dong H; Sun C; Liu L; Wang D; Wei Z
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):877-81. PubMed ID: 20840817
[TBL] [Abstract][Full Text] [Related]
19. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
